The C242T CYBA polymorphism as a major determinant of NADPH oxidase activity in patients with cardiovascular disease

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 7, Issue 3, 2009, Pages 251-259

  Mehranpour, P ^a,c   Wang, S S ^a,c   Blanco, R R ^a,c   Li, W ^a,c   Song, Q ^d   Lassegue B ^a   Dikalov, S I ^a   Austin, H ^b   Zafari, A M ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Coronary heart disease; CYBA; Functional genomics; Genetic association; Genotype phenotype relationship; NADPH oxidase; SNP

Indexed keywords

CYTOCHROME B; CYTOCHROME B245 ALPHA; CYTOSINE; OXIDOREDUCTASE; PROTEIN P22; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; THYMINE; UNCLASSIFIED DRUG;

ADULT; ANGIOCARDIOGRAPHY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DISEASE SEVERITY; ELECTRON SPIN RESONANCE; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; FEMALE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN BLOTTING;

ADULT; AGED; CARDIOVASCULAR DISEASES; CELL LINE; COHORT STUDIES; FEMALE; GENE EXPRESSION; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; NADPH OXIDASE; POLYMORPHISM, SINGLE NUCLEOTIDE; SUPEROXIDES;

EID: 70349480683     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152509789105417     Document Type: Review

References (73)

1. Griendling, K.K.; Sorescu, D.; Ushio-Fukai, M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res., 2000, 86(5), 494.
2. Jarasch, E.D.; Grund, C.; Bruder, G.; Heid, H.W.; Keenan, T.W.; Franke, W.W. Localization of xanthine oxidase in mammary-gland epithelium and capillary endothelium. Cell, 1981, 25(1), 67.
3. Xia, Y.; Tsai, A.L.; Berka, V.; Zweier, J.L. Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J. Biol. Chem., 1998, 273(40), 25804.
4. Vasquez-Vivar, J.; Kalyanaraman, B.; Martasek, P.; Hogg, N.; Masters, B.S.; Karoui, H.; Tordo, P.; Pritchard, K.A., Jr. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc. Natl. Acad. Sci. USA, 1998, 95(16), 9220.
5. Romano, M.; Claria, J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J., 2003, 17(14), 1986.
6. Chance, B.; Sies, H.; Boveris, A. Hydroperoxide metabolism in mammalian organs. Physiol. Rev., 1979, 59(3), 527.
7. Griendling, K.K.; Ushio-Fukai, M. Reactive oxygen species as mediators of angiotensin II signaling. Regul. Pept., 2000, 91(1-3), 2.
8. Stocker, R.; Keaney, J.F., Jr. Role of oxidative modifications in atherosclerosis. Physiol. Rev., 2004, 84(4), 1381.
9. Leopold, J.A.; Loscalzo, J. Oxidative enzymopathies and vascular disease. Arterioscler. Thromb. Vasc. Biol., 2005, 25(7), 1332.
10. Laursen, J.B.; Rajagopalan, S.; Galis, Z.; Tarpey, M.; Freeman, B.A.; Harrison, D.G. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation, 1997, 95(3), 588.
11. Taniyama, Y.; Griendling, K.K. Reactive oxygen species in the vasculature. Hypertension, 2003, 42, 1075.
12. Zafari, A.M.; Ushio-Fukai, M.; Akers, M.; Yin, Q.; Shah, A.; Harrison, D.G.; Taylor, W.R.; Griendling, K.K. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension, 1998, 32(3), 488.
13. phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J. Biol. Chem., 1996, 271(38), 23317.
14. Jones, S.A.; O'Donnell, V.B.; Wood, J.D.; Broughton, J.P.; Hughes, E.J.; Jones, O.T. Expression of phagocyte NADPH oxidase components in human endothelial cells. Am. J. Physiol., 1996, 271(4 Pt 2), H1626-34.
15. Pagano, P.J.; Clark, J.K.; Cifuentes-Pagano, M.E.; Clark, S.M.; Callis, G.M.; Quinn, M.T. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc. Natl. Acad. Sci. USA, 1997, 94(26), 14483.
16. Bendall, J.K.; Cave, A.C.; Heymes, C.; Gall, N.; Shah, A.M. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation, 2002, 105(3), 293.
17. Griendling, K.K.; Ollerenshaw, J.D.; Minieri, C.A.; Alexander, R.W. Angiotensin II stimulates NADH and NADPH activity in cultured vascular smooth muscle cells. Circ. Res., 1994, 74, 1141.
18. Bedard, K.; Krause, K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev., 2007, 87(1), 245.
19. DeLeo, F.R.; Burritt, J.B.; Yu, L.; Jesaitis, A.J.; Dinauer, M.C.; Nauseef, W.M. Processing and maturation of flavocytochrome b558 include incorporation of heme as a prerequisite for heterodimer assembly. J. Biol. Chem., 2000, 275(18), 13986.
20. phox). Gene structure, chromosomal location, and mutations in cytochrome-negative autosomal recessive chronic granulomatous disease. J. Clin. Invest., 1990, 86(5), 1729.
21. Roos, D.; de Boer, M.; Kuribayashi, F.; Meischl, C.; Weening, R.S.; Segal, A.W.; Ahlin, A.; Nemet, K.; Hossle, J.P.; Bernatowska-Matuszkiewicz, E.; Middleton-Price, H. Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Blood, 1996, 87, 1663.
22. Leusen, J.H.; Bolscher, B.G.; Hilarius, P.M.; Weening, R.S.; Kaulfersch, W.; Seger, R.A.; Roos, D.; Verhoeven, A.J. 156Pro - >Gln substitution in the light chain of cytochrome b558 of the human NADPH oxidase (p22-phox) leads to defective translocation of the cytosolic proteins p47-phox and p67-phox. J. Exp. Med., 1994, 180(6), 2329.
23. Adams, V.; Linke, A.; Kränkel, N.; Erbs, S.; Gielen, S.; Möbius-Winkler, S.; Gummert, J.F.; Mohr, F.W.; Schuler, G.; Hambrecht, R. Impact of regular physical activity on the NAD(P)H oxidase and angiotensin receptor system in patients with coronary artery disease. Circulation, 2005, 111, 555.
24. Lassègue, B.; Clempus, R.E. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2003, 285, R277-R297.
25. phox in human coronary arteries. Circulation 1999, 100, 1494.
26. Guzik, T.J.; West, N.E.J.; Black, E.; McDonald, D.; Ratnatunga, C.; Pillai, R.; Channon, K.M. Vascular superoxide production by NAD(P)H oxidase; Association with endothelial dysfunction and clinical risk factors. Circ. Res., 2000, 86, e85-e90.
27. phox gene on vascular superoxide production in atherosclerosis. Circulation, 2000, 102, 744.
28. phox; Expression and NADPH oxidase activity in hypertension. Hypertension, 2004, 44, 163.
29. phox A640G gene polymorphism but not the C242T gene variation is associated with coronary heart disease in younger individuals. Atherosclerosis, 1999, 145, 315.
30. phox gene: identification of a new polymorphism associated with hypertension. FEBS Lett., 2003, 542, 27.
31. phox, involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. Circ. Res., 2000, 86, 391.
32. Guzik, T.J.; West, N.E.; Black, E.; McDonald, D.; Ratnatunga, C.; Pillai, R.; Channon, K.M. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation, 2000, 102(15), 1744.
33. Li, A.; Prasad, A.; Mincemoyer, R.; Satorius, C.; Epstein, N.; Finkel, T.; Quyyumi, A.A. Relationship of the C242T p22phox gene polymorphism to angiographic coronary artery disease and endothelial function. Am. J. Med. Genet., 1999, 86(1), 57.
34. Yamada, Y.; Izawa, H.; Ichihara, S.; Takatsu, F.; Ishihara, H.; Hirayama, H.; Sone, T.; Tanaka, M.; Yokota, M. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N. Engl. J. Med., 2002, 347, 1916.
35. Arca, M.; Conti, B.; Montali, A.; Pignatelli, P.; Campagna, F.; Barilla, F.; Tanzilli, G.; Verna, R.; Vestri, A.; Gaudio, C.; Violi, F. C242T polymorphism of NADPH oxidase p22phox and recurrence of cardiovascular events in coronary artery disease. Arterioscler. Thromb. Vasc. Biol., 2008, 28(4), 752.
36. Kuroda, J.; Kitazono, T.; Ago, T.; Ninomiya, T.; Ooboshi, H.; Kamouchi, M.; Kumai, Y.; Hagiwara, N.; Yoshimura, S.; Tamaki, K.; Kusuda, K.; Fujii, K.; Nagao, T.; Okada, Y.; Toyoda, K.; Nakane, H.; Sugimori, H.; Yamashita, Y.; Wakugawa, Y.; Asano, K.; Tanizaki, Y.; Kiyohara, Y.; Ibayashi, S.; Iida, M. NAD(P)H oxidase p22phox C242T polymorphism and ischemic stroke in Japan: the Fukuoka Stroke Registry and the Hisayama study. Eur. J. Neurol., 2007, 14(10), 1091.
37. Genius, J.; Grau, A.J.; Lichy, C. The C242T polymorphism of the NAD(P)H oxidase p22phox subunit is associated with an enhanced risk for cerebrovascular disease at a young age. Cerebrovasc. Dis., 2008, 26(4), 430.
38. Ivanov, V.P.; Solodilova, M.A.; Polonikov, A.V.; Khoroshaia, I.V.; Kozhukhov, M.A.; Panfilov, V.I. [Association of C242T and A640G polymorphisms in the gene for p22phox subunit of NADPH oxidase with the risk of bronchial asthma: a pilot study]. Genetika, 2008, 44(5), 693.
39. Matsunaga-Irie, S.; Maruyama, T.; Yamamoto, Y.; Motohashi, Y.; Hirose, H.; Shimada, A.; Murata, M.; Saruta, T. Relation between development of nephropathy and the p22phox C242T and receptor for advanced glycation end product G1704T gene polymorphisms in type 2 diabetic patients. Diabetes Care, 2004, 27(2), 303.
40. Santos, K.G.; Canani, L.H.; Gross, J.L.; Tschiedel, B.; Souto, K.E.; Roisenberg, I. Relationship of p22phox C242T polymorphism with nephropathy in type 2 diabetic patients. J. Nephrol., 2005, 18(6), 733.
41. Nakano, T.; Matsunaga, S.; Nagata, A.; Maruyama, T. NAD(P)H oxidase p22phox Gene C242T polymorphism and lipoprotein oxidation. Clin. Chim. Acta, 2003, 335(1-2), 101.
42. Hayaishi-Okano, R.; Yamasaki, Y.; Ohtoshi, K.; Yasuda, T.; Katakami, N.; Hirano, T.; Yoshino, G.; Kajimoto, Y.; Hori, M. NAD (P) H oxidase p22 phox C242T polymorphism affects LDL particle size and insulin resistance in Japanese subjects. J. Atheroscler. Thromb., 2002, 9(4), 200.
43. Escobales, N.; Crespo, M.J. Oxidative-nitrosative stress in hypertension. Curr. Vasc. Pharmacol., 2005, 3(3), 231.
44. Zalba, G.; San Jose, G.; Moreno, M.U.; Fortuno, A.; Diez, J. NADPH oxidase-mediated oxidative stress: genetic studies of the p22(phox) gene in hypertension. Antioxid. Redox Signal., 2005, 7(9-10), 1327.
45. Tahara, T.; Arisawa, T.; Fujita, H.; Kamiya, Y.; Nagasaka, M.; Iwata, M.; Wang, F.; Shibata, T.; Nakamura, M.; Yoshioka, D.; Okubo, M.; Takahama, K.; Watanabe, M.; Nakano, H.; Hirata, I., No association between a genetic variant of the p22PHOX component of NADPH oxidase C242T and ulcerative colitis. Hepatogastroenterology, 2008, 55(86-87), 1573.
46. Nibali, L.; Parkar, M.; Brett, P.; Knight, J.; Tonetti, M.S.; Griffiths, G.S. NADPH oxidase (CYBA) and FcgammaR polymorphisms as risk factors for aggressive periodontitis: a case-control association study. J. Clin. Periodontol., 2006, 33(8), 529.
47. Tikly, M.; Gulumian, M.; Marshall, S. Lack of association of eNOS(G894T) and p22phox NADPH oxidase submit (C242T) polymorphisms with systemic sclerosis in a cohort of French Caucasian patients. Clin. Chim. Acta, 2005, 358(1-2), 196.
48. Park, J.Y.; Ferrell, R.E.; Park, J.J.; Hagberg, J.M.; Phares, D.A.; Jones, J.M.; Brown, M.D. NADPH oxidase p22phox gene variants are associated with systemic oxidative stress biomarker responses to exercise training. J. Appl. Physiol., 2005, 99(5), 1905.
49. phox polymorphisms in patients with coronary artery disease. Antioxid. Redox Signal., 2002, 4(4), 675.
50. Wyche, K.E.; Wang, S.S.; Griendling, K.K.; Dikalov, S.I.; Austin, H.; Rao, S.; Fink, B.; Harrison, D.G.; Zafari, A.M. C242T CYBA polymorphism of the NADPH oxidase is associated with reduced respiratory burst in human neutrophils. Hypertension, 2004, 43, 1246.
51. Whitworth, J.A. World Health Organization ISoHWG. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J. Hypertens., 2003, 21(11), 1983.
52. Alberti, K.G.; Zimmet, P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med., 1998, 15(7), 539.
53. Dash, H.; Johnson, R.A.; Dinsmore, R.E.; Harthorne, J.W. Cardiomyopathic syndrome due to coronary artery disease. I: relation to angiographic extent of coronary disease and to remote myocardial infarction. Br. Heart J., 1977, 39(7), 733.
54. Wang, S.S.; Tondella, M.; Bajpai, A.; Mathew, A.G.; Mehranpour, P.; Li, W.; Kacharava, A.G.; Fields, B.S.; Austin, H.; Zafari, A.M. Circulating Chlamydia pneumoniae DNA and advanced coronary artery disease. Int. J. Cardiol., 2007, 118(2), 215.
55. Neitzel, H. A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum. Genet., 1986, 73(4), 320.
56. Dikalov, S.I.; Li, W.; Mehranpour, P.; Wang, S.S.; Zafari, A.M. Production of extracellular superoxide by human lymphoblast cell lines: Comparison of electron spin resonance techniques and cytochrome C reduction assay. Biochem. Pharmacol., 2007, 73(3), 972.
57. Mander, A.P. Haplotype analysis in population-based association studies. Stata. J., 2001, 3(3), 58.
58. Carlin, J.B.; Greenwood, P.; Coffey, C. Tool for analyzing multiple imputed data sets. Stata. J., 2003, 3(3), 226.
59. Rubin, D. Inference and missing data (with discussion). Biometrika 1976, 63, 581.
60. phox gene polymorphism is associated with improved coronary endothelial vasodilator function. Eur. Heart J., 2001, 22(1), 96.
61. phox gene polymorphism to angiographic coronary artery disease and endothelial function. Am. J. Med. Genet., 1999, 86, 57.
62. Dusi, S.; Nadalini, K.A.; Donini, M.; Zentilin, L.; Wientjes, F.B.; Roos, D.; Giacca, M.; Rossi, F. Nicotinamide-adenine dinucleotide phosphate oxidase assembly and activation in EBV-transformed B lymphoblastoid cell lines of normal and chronic granulomatous disease patients. J. Immunol., 1998, 161(9), 4968.
63. Hancock, J.T.; Henderson, L.M.; Jones, O.T.G. Superoxide generation by EBV-transformed B-lymphocytes. Immunology, 1990, 71, 213.
64. phox in lymphoblast cell lines. J. Hypertens., 2002, 20(4), 677.
65. Lee, V.M.; Quinn, P.A.; Jennings, S.C.; Ng, L.L. NADPH oxidase activity in preeclampsia with immortalized lymphoblasts used as models. Hypertension, 2003, 41, 925.
66. phox gene in patients with coronary artery disease. Circulation, 1998, 97, 135.
67. Luo, A.K.; Jefferson, B.K.; Garcia, M.J.; Ginsburg, G.S.; Topol, E.J. Challenges in the phenotypic characterization of patients in genetic studies of coronary artery disease. J. Med. Genet., 2007, 44, 161.
68. Fayad, Z.A.; Fuster, V.; Nikolaou, K.; Becker, C. Computed tomography and magnetic resonance imaging for noninvasive coronary angiography and plaque imaging: Current and potential future concepts. Circulation, 2002, 106(15), 2026.
69. phox component of NAD(P)H oxidase with susceptibility to diabetic nephropathy in patients with type 1 diabetes. Diabetes Care, 2003, 26(11), 3111.
70. Doi, K.; Noiri, E.; Nakao, A.; Fujita, T.; Kobayashi, S.; Tokunaga, K. Haplotype analysis of NAD(P)H oxidase p22 phox polymorphisms in end-stage renal disease. J. Hum. Genet., 2005, 50(12), 641.
71. Cohen, J.C. Genetic approaches to coronary heart disease. J. Am. Coll. Cardiol., 2006, 48(9Suppl. 1), A10-4.
72. Soccio, M.; Toniato, E.; Evangelista, V.; Carluccio, M.; De Caterina, R. Oxidative stress and cardiovascular risk: the role of vascular NAD(P)H oxidase and its genetic variants. Eur. J. Clin. Invest., 2005, 35(5), 305.
73. Boerwinkle, E.; Ellsworth, D.L.; Hallman, D.M.; Biddinger, A. Genetic analysis of atherosclerosis: a research paradigm for the common chronic diseases. Hum. Mol. Genet., 1996, 5 Spec No, 1405-10.